We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 57.33-0.2%3:59 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (3081)10/21/2018 10:58:58 AM
From: tuck  Read Replies (2) of 3202
No chatter here on the FGFR inhibitor. Data that superficially looks better than ARQL's competing drug at ESMO, including an ORR twice that of ARQL's:

Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma

But, one biotweeter says the baseline patient population is different, with the INCY cohorts having better ECOG status, and exclusion of patient with prior systemic treatment for unresectable or metastatic disease. That information might be confirmable just by looking at clinical, but I'm not going to do that just now. If someone else doesn't, I might do it later.

Dunno what the market is for cholangiocarcinoma (incidence/prevalence, etc.)

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext